Research
Energy balance
GLP-1 receptor agonists promote weight loss, with short-acting formulations (exenatide twice daily) often producing greater weight reduction than once-weekly formulations (exenatide once weekly, albiglutide, dulaglutide).
GLP-1 drugs are effective for weight loss. Short-acting versions (taken twice daily) tend to cause more weight loss than once-weekly versions. If weight loss is your primary goal, discuss short-acting options with your doctor. Be prepared for potential nausea, which often improves over time.
GoodSupportsHIGH confidence
Liraglutide was associated with weight reductions similar to those with exenatide twice daily but greater than those with exenatide once weekly, albiglutide and dulaglutide.
Why this rating
Based on multiple phase III trials showing consistent weight reduction trends.
Source
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Sten Madsbad · Diabetes Obesity and Metabolism · 2015
DOI 10.1111/dom.12596
narrative_reviewCited 292×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →